pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
mRNA Therapeutic · news · pharmadog
← back to mRNA Therapeutic
News · mRNA Therapeutic
172
stories
2h
Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform
endpoints
4h
How AI is transforming biopharma manufacturing facilities of the future
biopharma dive
4h
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
stat
2d
What it’s like to wait for the call from the Nobel Prize committee
stat
2d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
2d
Foghorn cuts 40% of workforce
biospace
2d
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
2d
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
3d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
3d
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board
endpoints
3d
Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
endpoints
3d
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
3d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
4d
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
stat
5d
BioNTech to close German manufacturing plants after failing to find buyers
biospace
5d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
10d
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
10d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
12d
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
12d
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
biospace
14d
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
biospace
19d
Skyhawk racks up more support for Huntington’s drug
biopharma dive
21d
Cyclic peptides open new drug frontiers, if manufacturing can keep up
biospace
21d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
21d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
24d
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
26d
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
biospace
26d
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
27d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
← prev
page 1 of 6
next →
